Predictive value of stimulated thyroglobulin and thyroglobulin reduction index in 131I treatment response in postoperative patients with thyroid cancer
10.3760/cma.j.cn113855-20211006-00583
- VernacularTitle:刺激性甲状腺球蛋白和甲状腺球蛋白减少指数对甲状腺癌术后患者行 131I治疗反应分级的预测价值
- Author:
Zhipeng LI
1
;
Ming LI
;
Dou KANG
;
Peng FU
Author Information
1. 哈尔滨医科大学附属第一医院核医学科，哈尔滨 150001
- Keywords:
Thyroid neoplasms;
Thyroglobulin;
Forecasting
- From:
Chinese Journal of General Surgery
2022;37(8):584-587
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the predictive value of pre-ablation stimulated thyroglobulin (Pre-sTg) and thyroglobulin reduction index (TRI) before 131I treatment for prognosis improvement in medium-low risk differentiated thyroid carcinoma (DTC) patients. Methods:One hundred and ninty-four patients with low-medium risk DTC who received 131I treatment at the Department of Nuclear Medicine of our hospital from July 2019 to June 2021 were included in to this prospective study. Multifactor Logistic regression analysis was performed to evaluate the influence on the prognosis of DTC patients. Results:Pre-sTg and TRI were the prognostic factors for radioiodine remnant ablation (RRA) ( P<0.05). When the cut off value for Pre-sTg was ≤8.64 ng/ml, the sensitivity, specificity, positive predictive value, negative predictive value and crude agreement for Pre-sTg were 71.43%, 62.96%, 83.33%, 62.96% and 69.07%. While the cut off value for TRI was >84.80%, the sensitivity, specificity, positive predictive value, negative predictive value and crude agreement for TRI were 54.29%, 70.37%, 81.72%, 28.24% and 58.25%. Conclusions:Pre-sTg and TRI are independent predictors of the efficacy of radioiodine remnant ablation (RRA), and can be used for early prediction of the efficacy of RRA treatment.
